Europe · Business news · Corporate · 01 Oct 2026
EU Health Care
Germany's Fresenius SE is acquiring the 45% of mAbxience it did not already own, for a price of up to €750 million, taking the biosimilars developer and manufacturer to full ownership.
Full ownership means Fresenius keeps all of mAbxience's profit instead of sharing 45% with minority holders, and controls its biosimilar pipeline and manufacturing capacity outright within its Kabi division. The price is 'up to' €750 million, which indicates part of it depends on future milestones. Against the size of Fresenius the outlay is modest; the effect is on the biopharma segment's earnings share rather than on group leverage.
Reported by Newsquawk — “Newsquawk Daily European Equity Opening News - 1st October 2026” ↗ on 01 Oct 2026.
Official series on 01 Oct 2026 or the last day before it, and the latest observation.
Fresenius Medical Care runs 3,513 dialysis clinics treating about 290,000 patients, and under Giza it finished a programme that took about €1.2 billion out of its cost base. The change comes with five days' notice…
The move in French debt matters most to banks and insurers that hold it and to French companies whose borrowing costs follow the sovereign; it reverses part of the sell-off that took the CAC 40 to a six-month low on…
The increase answers activist investor Palliser Capital, which argued the first price undervalued the company and asked for at least €60 a share; the new terms are still well below that, so minority holders now choose…
Epcoritamab, sold as EPKINLY in the US and Japan and TEPKINLY in the EU, is approved so far for lymphoma that has returned after earlier treatment. A first-line label would open a much larger group of patients, and…
All European business stories · Every market · What changed today